Stockhead reports Race gets ethics nod for Phase I trial in solid tumour patients
Stockhead reports Race gets ethics nod for Phase I trial in solid tumour patients
Race Oncology Executive Chair Dr Peter Smith speaks with Stockhead about the recent ethics approval for the company’s RC220 bisantrene Phase 1 clinical trial in solid tumour. The full report can be accessed via...
Proactive: Race Oncology’s RC220 trial gets green light
Proactive: Race Oncology’s RC220 trial gets green light
Race Oncology Executive Chair Dr Peter Smith speak with Proactive about the approval the company has received from the Bellberry Human Research Ethics Committee (HREC). The approval allows the company to move forward with...
ausbiz speaks with Race CEO on the Phase 1 trial ethics approval
ausbiz speaks with Race CEO on the Phase 1 trial ethics approval
Race CEO and Managing Director Dr Daniel Tillett speaks with ausbiz’s Juliette Saly about the ethics approval for the RC220 bisantrene Phase 1 clinical trial. Watch the full video via this link....
Proactive – Daniel Tillett on Race Oncology’s drug advancements
Proactive – Daniel Tillett on Race Oncology’s drug advancements
Race CEO and Managing Director Dr Daniel Tillett speaks with Proactive about the company’s development of a reformulated cancer drug aimed at improving chemotherapy treatment. Dr Tillett discussed the challenges of chemotherapy, including severe...
Proactive: Oncology market projected to soar in 2025 and beyond
Proactive: Oncology market projected to soar in 2025 and beyond
Proactive reports on the outlook of the oncology therapeutics market, naming Race Oncology, alongside its peer companies, one of the most promising to look out for. Read the full article via this link....
Road to 2025: Race on track with clinical trials
Road to 2025: Race on track with clinical trials
Stockhead’s Road to 2025 video series highlights companies’ key 2024 achievements and the routes they’re plotting towards a successful year ahead. In this episode, Fraser Palamara takes a look at Race Oncology (ASX:RAC). Watch the video...
Behind Race Oncology’s quest to prevent chemo from being worse than the disease
Behind Race Oncology’s quest to prevent chemo from being worse than the disease
Race Oncology is reformulating bisantrene (RAC-220) to prevent chemotherapy-induced heart damage, with a phase 1 cardioprotection trial planned for early 2025. The trial will enroll 25-40 patients across multiple sites. The company has also...
The Australian: Race Oncology bolsters leadership with key appointment
The Australian: Race Oncology bolsters leadership with key appointment
As seen in The Australian, Dr Megan Baldwin joins the Race board as Non-Executive Director. Dr Baldwin is a seasoned biotech executive with more than 25 years of experience. She is the Founder and...
Proactive: Race Oncology secures A$5.25 million R&D tax rebate for FY2024
Proactive: Race Oncology secures A$5.25 million R&D tax rebate for FY2024
Proactive reports on Race’s R&D tax rebate and clinical progress made in FY 2024. Read the full article here....
The Australian: Race submits key ethics application for phase I cancer trial
The Australian: Race submits key ethics application for phase I cancer trial
Conducted in two stages, the Phase 1 clinical trial will examine the safety and tolerability of the reformulated bisantrene, RC220, in particular the drug’s cardioprotective ability when used in combination with doxorubicin, a form...
